Stemming from the results above, to better investigate the role of mutated‐PlxnB2 in tumor progression, we generated agnosphere‐derived xenograft (ADX) preclinical models, as described previously (Verginelli et al, 2021); thus, we injected subcutaneously in NOD‐SCID mice either control or PlxnB2‐depleted AS43 or AS901 CUP models and monitored tumor growth by periodical calibration. This evidence concerns the gene PLXNB2 and neoplasm.